Roivant Sciences (NASDAQ:ROIV) Director Sells $30,519,062.74 in Stock

Roivant Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Roivant director Daniel Gold sold 779,741 shares for about $30.5 million at an average $39.14, reducing his holdings by 46.11% to 911,127 shares. He also sold 602,021 shares the following day for about $23.0 million.
  • Analyst sentiment is broadly positive: Roivant has a “Moderate Buy” consensus and an average price target of $46.82, with recent targets raised to $48 by HC Wainwright and Guggenheim.
  • ROIV rose 0.1% to $38.73 in Wednesday midday trading; its 52-week range is $19.96 to $42.50.
  • Five stocks we like better than Roivant Sciences.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Daniel Gold sold 779,741 shares of the company's stock in a transaction on Monday, November 16th. The shares were sold at an average price of $39.14, for a total transaction of $30,519,062.74. Following the transaction, the director owned 911,127 shares of the company's stock, valued at approximately $35,661,510.78. The trade was a 46.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Daniel Allen Gold also recently made the following trade(s):

  • On Tuesday, November 17th, Daniel Gold sold 602,021 shares of Roivant Sciences stock. The stock was sold at an average price of $38.24, for a total transaction of $23,021,283.04.

Roivant Sciences Stock Up 0.1%

NASDAQ ROIV traded up $0.02 during midday trading on Wednesday, hitting $38.73. The company had a trading volume of 3,724,435 shares, compared to its average volume of 6,586,585. The firm has a fifty day simple moving average of $37.32 and a two-hundred day simple moving average of $32.42. Roivant Sciences Ltd. has a fifty-two week low of $19.96 and a fifty-two week high of $42.50. The stock has a market cap of $28.06 billion, a price-to-earnings ratio of -61.48 and a beta of 1.23.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ROIV shares. HC Wainwright upped their price target on Roivant Sciences from $47.00 to $48.00 and gave the company a "buy" rating in a report on Tuesday, November 10th. Guggenheim lifted their price objective on Roivant Sciences from $46.00 to $48.00 and gave the stock a "buy" rating in a report on Monday. Wolfe Research cut Roivant Sciences from an "outperform" rating to a "peer perform" rating in a research report on Monday, October 12th. Bank of America reiterated a "neutral" rating on shares of Roivant Sciences in a research note on Friday, July 31st. Finally, Sanford C. Bernstein upgraded shares of Roivant Sciences to a "strong-buy" rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Roivant Sciences has a consensus rating of "Moderate Buy" and a consensus price target of $46.82.

View Our Latest Stock Analysis on ROIV

Institutional Investors Weigh In On Roivant Sciences

Hedge funds have recently made changes to their positions in the company. Alpine Bank Wealth Management acquired a new stake in Roivant Sciences in the third quarter worth about $25,000. Compass Financial Management LLC acquired a new position in Roivant Sciences during the 3rd quarter valued at about $37,000. Kovack Advisors Inc. acquired a new position in Roivant Sciences during the 3rd quarter valued at about $47,000. Parallel Advisors LLC lifted its position in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock valued at $57,000 after purchasing an additional 520 shares during the period. Finally, Bessemer Group Inc. boosted its stake in shares of Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock valued at $69,000 after purchasing an additional 441 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Recommended Stories

Insider Buying and Selling by Quarter for Roivant Sciences (NASDAQ:ROIV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Roivant Sciences Right Now?

Before you consider Roivant Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.

While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines